• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Cytogenetic Subgroup Analysis from POLLUX

byKathleen Lau
December 10, 2020
in StudyGraphics
0
Share on FacebookShare on Twitter

RELATED REPORTS

World Health Organization warns that one in six infections now antibiotic resistant

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial

Increasing cancer incidence rates in younger and older adults worldwide

Tags: bloodblood cancercancerchemotherapycytogeneticsdaratumumabdexamethasonehematologylenalidomidemultiple myelomamyelomaoncologyrelapsed and refractory multiple myeloma
Previous Post

#VisualAbstract: Increased incidence of sebaceous carcinomas among solid organ transplant recipients

Next Post

Oxygenated hypothermic perfusion reduces post-kidney transplant complications

RelatedReports

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
The Scan by 2 Minute Medicine®

World Health Organization warns that one in six infections now antibiotic resistant

October 23, 2025
Lessons from real-world implementation of lung cancer screening
Chronic Disease

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial

October 22, 2025
Population-based risk factors and geographical trends identified for vitiligo
Oncology

Increasing cancer incidence rates in younger and older adults worldwide

October 20, 2025
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Chronic Disease

Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study

October 13, 2025
Next Post

Oxygenated hypothermic perfusion reduces post-kidney transplant complications

Quick Take: Diffusion-weighted Imaging of Invasive Breast Cancer: Relationship to Distant Metastasis–free Survival

Pembrolizumab plus chemotherapy improves survival in patients with metastatic triple-negative breast cancer

#VisualAbstract CONTRALTO Phase II: Venetoclax-Rituximab With or Without Bendamustine VS Bendamustine-Rituximab in Relapsed/Refractory Follicular Lymphoma

#VisualAbstract CONTRALTO Phase II: Venetoclax-Rituximab With or Without Bendamustine VS Bendamustine-Rituximab in Relapsed/Refractory Follicular Lymphoma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes
  • New York confirms first locally acquired chikungunya case in six years
  • Smartphone-Based Muscle Relaxation for Migraine in the Emergency Department
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.